medigraphic.com
ISSN 1561-2937 (Print)

2021, Number 3

<< Back Next >>

Rev Cubana Cardiol Cir Cardiovasc 2021; 27 (3)

Statins in COVID-19, role and benefits

Ortega TYY, Valdés MA, Armas RNB, Llanes EJR, García GY

Language: Spanish
References: 25
Page: 1-6
PDF size: 381.40 Kb.


ABSTRACT

The severe acute respiratory syndrome (SARS-CoV-2) produced by the type 2 coronavirus (SARS-CoV-2) is responsible for the COVID-19 pandemic and it also has caused a global health crisis. COVID-19 is now recognized as a multiorgan disease with a wide spectrum of manifestations beyond the acute phase of infection. It occurs due to an exaggerated inflammatory response that causes the release of pro-inflammatory cytokines such as interleukins and tumor necrosis factor alpha (TNF-α). Statins are lipid-lowering drugs with pleiotropic effects that have shown benefits in the management of inflammatory and autoimmune diseases. The immunomodulatory properties of statin have been used in the treatment of various infectious diseases such as community-acquired pneumonia and influenza. In this review we analyze the scientific rationale supporting the use of statins as adjunctive treatment in patients with COVID-19.


REFERENCES

  1. Wu F., Zhao S., Yu B., Chen Y.M., Wang W., Song Z.G. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579:265–269.

  2. Organización Panamericana de la Salud / Organización Mundial de la Salud. Actualización epidemiológica: Enfermedad por Coronavirus (COVID-19). 11 de marzo de 2021, Washington, D.C.: OPS/OMS; 2021 Organización Panamericana de la Salud • www.paho.org• © OPS/OMS, 202.

  3. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382:1708–1720.

  4. Zeiser R. Inmune modulatory effects of statins. Immunology. 2018; 154:69–75.

  5. Agnieszka P., Mateusz N., Paulina G., Marlena B., Ewelina W.COVID-19: Direct and Indirect Mechanisms of Statins.Review Int J Mol Sci. 2021 17;22(8):4177.

  6. Fotios B, Haralampos M., Georgia A., Evangelos L. Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019? Med Hypotheses 2021; 146:110452.

  7. Mehra M.R., Desai S.S., Kuy S., Henry T.D., Patel A.N. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382:e102

  8. Fedson D.S. Treating influenza with statins and other immunomodulatory agents. Antiviral Res.2013; 99:417–435.

  9. Garnacho Montero J., Barrero-García I., Gómez Prieto M.G., Martín Loeches I. Severe community-acquired pneumonia: current management and future therapeutic alternatives. Expert Rev Anti Infect Ther.2018; 16:667–677.

  10. Aparisi A, Amat-Santos IJ, López Otero D, Mangas Marcos M, Juanatey González JR, San Romàn A. Impacto de las estatinas en los pacientes con COVID-19.Rev Esp Cardiol. 2021;74(7): 637-640.

  11. Zhang X et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metabolism 32, 1–12, August 4, 2020.

  12. Vaduganathan M., Vardeny O., Michel T., McMurray J.J.V., Pfeffer M.A., Solomon S.D. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020; 382:1653–1659.

  13. Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181:271–280.

  14. South A.M., Diz D.I, Chappell M.C. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020; 318:H1084–H1090-

  15. Totura A.L, Whitmore A., Agnihothram S., Schäfer A, Katze M.G., Heise M.T. Toll-like receptor 3 signalling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection.mBio. 2015; 6:e00638–e715.

  16. Sheahan T, Morrison T.E., Funkhouser W., Uematsu S, Akira S, Baric R.S. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog. 2008;4:e1000240.

  17. De Diego M.L., Nieto-Torres J.L., Regla-Nava J.A., Jimenez-Guardeño J.M., Fernandez-Delgado R., Fett C. Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol. 2014; 88:913–924.

  18. Chansrichavala P., Chantharaksri U., Sritara P., Chaiyaroj S.C. Atorvastatin attenuates TLR4-mediated NF-kappa B activation in a MyD88-dependent pathway. Asian Pac J Allergy Immunol. 2009;27:49–57.

  19. Fedson D.S., Opal S.M., Rordam O.M. Hiding in plain sight: an approach to treating with severe COVID-19 infection. mBio. 2020; 11:e00398–e420.

  20. Castiglione V., Chiriacò M., Emdin M., Taddei S., Vergaro G. Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020; 6(4):258-259.

  21. Reiner Ž, Hatamipour M., Banach M., Pirro M., Al-Rasadi K., Jamialahmadi T. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci. 2020; 16:490–496.

  22. Xu L., Liu J., Lu M., Yang D., Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020; 40:998–1004.

  23. Newman C.B., Preiss D., Tobert J.A., Jacobson T.A., Page R.L.2nd, Goldstein L.B. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019; 39:e38–e81.

  24. Chalasani N., Aljadhey H., Kesterson J., Murray M.D., Hall S.D. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004; 126:1287–1292.

  25. Timotius I. Hariyanto a , Andree Kurniawan b. Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression. Nutrition, Metabolism and Cardiovascular Diseases. 2021; 31(6):1662-1670.




2020     |     www.medigraphic.com